CBL0137 – 10 mg

Brand:
Cayman
CAS:
1197996-80-7
Storage:
-20
UN-No:
Non-Hazardous - /

CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM.{30977} It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.{30977} CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine (Item No. 11690) in preclinical models of pancreatic cancer.{30977,30976}  

 

Available on backorder

SKU: - Category:

Description

A metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM; has broad anticancer activity in mice when administered orally


Formal name: 1,1′-[9-[2-[(1-methylethyl)amino]ethyl]-9H-carbazole-3,6-diyl]bis-ethanone

Synonyms:  CBLC137|Curaxin 137

Molecular weight: 336.4

CAS: 1197996-80-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Activators|Transcription Factors & Coactivators||Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cancer|Cell Signaling|NF-κB Signaling||Research Area|Cancer|Cell Signaling|p53 Signaling||Research Area|Cancer|Transcription Factors|NF-κB||Research Area|Cancer|Transcription Factors|p53||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Immunology & Inflammation|Innate Immunity|STING||Research Area|Infectious Disease